Landsberg Bennett & Dubbaneh’s Charles River Laboratories CRL Stock Holding History

Landsberg Bennett & Dubbaneh’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$4.43M	Sell	10,622 -2,000	-16%	-$831K	0.56%	51
2021 Q2	$4.69M	Buy	12,622 +280	+2%	+$93.5K	0.61%	44
2021 Q1	$3.63M	Sell	12,342 -1,025	-8%	-$285K	0.52%	52
2020 Q4	$3.34M	Sell	13,367 -385	-3%	-$91.7K	0.51%	57
2020 Q3	$3.07M	Buy	+13,752	New	+$2.85M	0.54%	48

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Landsberg Bennett & Dubbaneh's CRL Position: Q3 2021 in Review

Landsberg Bennett & Dubbaneh reduced its Charles River Laboratories (CRL) stake by 16% in Q3 2021, selling an estimated $831K and leaving 10,622 shares worth $4.43M. The position accounts for 0.56% of the portfolio, ranked #51.

Landsberg Bennett & Dubbaneh first reported a position in CRL in Q3 2020 and has held it in 5 quarters since. The position peaked at $4.69M in Q2 2021. 677 funds tracked by Wall St. Rank hold CRL as of Q3 2021.

Landsberg Bennett & Dubbaneh held 10,622 shares of Charles River Laboratories worth $4.43M as of Q3 2021.
Landsberg Bennett & Dubbaneh sold 2,000 Charles River Laboratories shares in Q3 2021, an estimated $831K.
Charles River Laboratories made up 0.56% of Landsberg Bennett & Dubbaneh's portfolio in Q3 2021, its #51 holding.
Landsberg Bennett & Dubbaneh first reported a position in Charles River Laboratories in Q3 2020 and has held it in 5 quarters since.
Landsberg Bennett & Dubbaneh's Charles River Laboratories position peaked at $4.69M in Q2 2021.
677 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2021.

Based on Landsberg Bennett & Dubbaneh's 13F filing for Q3 2021, filed 29 Oct 2021.